Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial

医学 静脉血栓栓塞 临床终点 打开标签 随机对照试验 外科 血栓形成
作者
Françis Couturaud,Jeannot Schmidt,Olivier Sanchez,Alice Ballerie,Marie‐Antoinette Sevestre,Nicolas Méneveau,Laurent Bertoletti,J. Connault,Y. Benhamou,J. Constans,T. Quéméneur,François-Xavier Lapébie,Gilles Pernod,Gaël Picart,Antoine Élias,C. Doutrelon,Claire Neveux,Lina Khider,P.M. Roy,Stéphane Zuily
出处
期刊:The Lancet [Elsevier BV]
卷期号:405 (10480): 725-735 被引量:1
标识
DOI:10.1016/s0140-6736(24)02842-3
摘要

In patients with venous thromboembolism at high risk of recurrence for whom extended treatment with direct oral anticoagulants has been indicated, the optimal dose is unknown. We aimed to assess efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom extended anticoagulation has been indicated. RENOVE was a non-inferiority, investigator-initiated, multicentre, randomised, open-label, blinded endpoint trial done in 47 hospitals in France. Ambulatory patients aged 18 years or older with acute symptomatic venous thromboembolism (pulmonary embolism or proximal deep vein thrombosis) who had received 6-24 uninterrupted months of full-dose anticoagulation and for whom extended anticoagulation has been indicated were eligible. Eligible participants were categorised as having either a first unprovoked venous thromboembolism, recurrent venous thromboembolism, presence of persistent risk factors, or other clinical situations considered to be a high risk of recurrence. Participants were randomly assigned (1:1) to receive oral treatment with either a reduced dose of apixaban (2·5 mg twice daily) or rivaroxaban (10 mg once daily) or a full dose of apixaban (5 mg twice daily) or rivaroxaban (20 mg once daily) using a centralised randomisation procedure with an interactive web response system. The sequence generation method was a computerised random number generator and was balanced by blocks of different sizes. Randomisation was stratified by centre, type of direct oral anticoagulant, and antiplatelet drug. Physicians and participants were unmasked to treatment allocation; recurrent venous thromboembolism, clinically relevant bleeding, and all-cause death were adjudicated by an independent committee blinded to treatment allocation. The primary outcome was symptomatic recurrent venous thromboembolism, including recurrent fatal or non-fatal pulmonary embolism or isolated proximal deep vein thrombosis (non-inferiority hypothesis 90% power to exclude a hazard ratio [HR] of 1·7). The primary outcome and first two secondary outcomes were included in a hierarchical testing procedure. This trial is registered with ClinicalTrials.gov, NCT03285438. From Nov 2, 2017, to July 6, 2022, 2768 patients were enrolled and randomly assigned to the reduced-dose group (n=1383) or the full-dose group (n=1385). 970 (35·0%) participants were female, 1797 (65·0%) were male, and one (<0·1%) had sex not reported. Median follow-up was 37·1 months (IQR 24·0-48·3). Recurrent venous thromboembolism occurred in 19 of 1383 patients in the reduced-dose group (5-year cumulative incidence 2·2% [95% CI 1·1-3·3]) versus 15 of 1385 patients in the full-dose group (5-year cumulative incidence 1·8% [0·8-2·7]; adjusted HR 1·32 [95% CI 0·67-2·60]; absolute difference 0·40% [95% CI -1·05 to 1·85]; p=0·23 for non-inferiority). Major or clinically relevant bleeding occurred in 96 patients in the reduced-dose group (5-year cumulative incidence 9·9% [95% CI 7·7-12·1]) and 154 patients in the full-dose group (5-year cumulative incidence 15·2% [12·8-17·6]; adjusted HR 0·61 [95% CI 0·48-0·79]). 1136 (82·1%) of 1383 patients in the reduced-dose group and 1150 (83·0%) of 1385 in the full-dose group had an adverse event; 374 (27·0%) patients in the reduced-dose group and 420 (30·3%) in the full-dose group has a serious adverse event. 35 (5-year cumulative incidence 4·3% [95% CI 2·6-6·0]) patients in the reduced-dose group and 54 (5-year cumulative incidence 6·1% [4·3-8·0]) patients in the full-dose group died during the study period. In patients with venous thromboembolism requiring extended anticoagulation, reduction of the direct oral anticoagulant dose did not meet the non-inferiority criteria. However, the low recurrence rates in both groups and substantial reduction of clinically relevant bleeding with the reduced dose could support this regimen as an option. Further research will be needed to identify subgroups for whom the anticoagulation dose should not be reduced. French Ministry of Health.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷波er应助科研通管家采纳,获得10
刚刚
Akim应助科研通管家采纳,获得10
刚刚
斯文败类应助科研通管家采纳,获得10
刚刚
MchemG应助科研通管家采纳,获得10
1秒前
英俊的铭应助科研通管家采纳,获得10
1秒前
CAOHOU应助科研通管家采纳,获得10
1秒前
1秒前
1秒前
2秒前
爱撞墙的猫完成签到,获得积分10
2秒前
小马甲应助干雅柏采纳,获得10
2秒前
小晓完成签到,获得积分10
2秒前
becky发布了新的文献求助10
3秒前
jszhoucl发布了新的文献求助10
4秒前
星期八发布了新的文献求助10
4秒前
时有落花至完成签到,获得积分10
4秒前
4秒前
无与伦比发布了新的文献求助30
8秒前
10秒前
一人独钓一江秋完成签到,获得积分10
10秒前
12秒前
13秒前
干雅柏发布了新的文献求助10
15秒前
搜集达人应助俏皮芷蕊采纳,获得10
17秒前
上官若男应助sugar采纳,获得10
18秒前
xxxllllll发布了新的文献求助30
18秒前
18秒前
CodeCraft应助wangqiuhong采纳,获得10
19秒前
21秒前
桐桐应助jszhoucl采纳,获得10
21秒前
黄健斌完成签到,获得积分10
22秒前
HarryChan完成签到,获得积分10
24秒前
27秒前
28秒前
28秒前
华仔应助小绵羊采纳,获得10
30秒前
Andema发布了新的文献求助10
31秒前
俏皮芷蕊发布了新的文献求助10
32秒前
33秒前
xiao_niu完成签到,获得积分10
33秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989444
求助须知:如何正确求助?哪些是违规求助? 3531531
关于积分的说明 11254250
捐赠科研通 3270191
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174